Initiate a randomized Phase 2 clinical trial of OTX-TIC in the United States
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- Q4 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company plans to initiate a randomized, double-masked, active-controlled Phase 2 clinical trial in mid-2021 in the United States with a total of approximately 105 subjects”
What we found
Evidence strength A What the grades mean
The Phase 2 trial was initiated in Q4 2021, after the mid-2021 target. Filings from August and November 2021 had moved the start to Q4 2021.
-
A Ocular Therapeutix, Inc. 8-K filed 2021-08-09
“the Company is targeting the initiation of a randomized, double-masked, active-controlled Phase 2 clinical trial in the fourth quarter of 2021 in the United States.” ✓ confirmed on the page
-
A Ocular Therapeutix, Inc. 10-Q filed 2021-11-08
“In the fourth quarter of 2021, we plan to initiate a randomized, double-masked, active-controlled Phase 2 clinical trial” ✓ confirmed on the page
-
A Ocular Therapeutix, Inc. 10-K filed 2022-02-28
“In the fourth quarter of 2021, we initiated a randomized, double-masked, active-controlled Phase 2 clinical trial in which we plan to enroll approximately 105 subjects” ✓ confirmed on the page
-
A Ocular Therapeutix, Inc. 10-K filed 2022-02-28
“We initiated the Phase 2 clinical trial in the fourth quarter of 2021 and expect to dose the first subject in the first quarter of 2022.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 trial of OTX-TIC in the United States
- Target
- 105 subjects
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ocular Therapeutix, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OCUL-025608 · Corrections policy